scholarly journals Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report

2020 ◽  
Author(s):  
Giovanna Impellizzeri ◽  
Matteo Renzulli ◽  
Francesco Azzaroli ◽  
Rita Golfieri ◽  
Giuseppe Mazzella ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Complete Remission ◽  
Gold Standard ◽  
Palliative Treatment ◽  
Retroperitoneal Fibrosis ◽  
Drug Discontinuation ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Therapy ◽  
First Case

Sorafenib is currently the gold standard therapy for palliative treatment of advanced hepatocellular carcinoma (HCC) in patients with compensated liver disease. There are few cases reported in literature describing patients with HCC achieving a complete remission (CR) due to Sorafenib therapy. We report the case of a 62-year old patient who obtained CR despite single, long drug discontinuation and kept it without any maintenance therapy. Furthermore, this is the first case describing the onset of a likely IgG4-related retroperitoneal fibrosis and cholangitis during Sorafenib administration. Further studies are required to define the predictors of a good response to Sorafenib and to codify a therapeutic maintenance regimen for patients who achieve CR.

scholarly journals Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report

2017 ◽  
Vol 14 (4) ◽  
pp. 4853-4856 ◽  
Author(s):  
Jung Gil Park ◽  
Won Young Tak ◽  
Soo Young Park ◽  
Young Oh Kweon ◽  
Se Young Jang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Complete Remission ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Therapy ◽  
Long Term Follow Up

scholarly journals Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report

2013 ◽  
Vol 5 (2) ◽  
pp. 38 ◽  
Author(s):  
Min Su Kim ◽  
Young-Joo Jin ◽  
Jin-Woo Lee ◽  
Jung-il Lee ◽  
Young Soo Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Complete Remission ◽  
Advanced Hepatocellular Carcinoma

scholarly journals Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series

2021 ◽  
pp. 224-231
Author(s):  
Richard T. Lee ◽  
Peiying Yang ◽  
Asrar Alahmadi ◽  
Jennifer McQuade ◽  
Eric Yuan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Time ◽  
Injection Site Reaction ◽  
Case Series ◽  
Advanced Hepatocellular Carcinoma ◽  
Site Reaction ◽  
Advanced Hcc ◽  
Mistletoe Extract ◽  
Sorafenib Therapy ◽  
Mistletoe Extracts

Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of death from cancer worldwide, and for advanced HCC the prognosis is poor. Preliminary studies indicate mistletoe extracts may have anticancer activity for HCC. Methods: A prospective observational case series of advanced HCC patients that chose to take a mistletoe extract called viscum fraxini-2 (VF-2) alone for treatment. Time on treatment, imaging, and laboratory values were collected for descriptive analyses. Results: A total of 12 patients with advanced HCC enrolled onto the protocol, and 10 patients had data available for evaluation. The majority were male (10/12) with a median age of 64 (SD 11). Most patients had received sorafenib therapy (9/12) and had varying Child-Pugh classes (A-4, B-6, C-2). Treatment with VF-2 ranged from 1 to 36 weeks with a mean of 12.3 weeks (SD 12). Six patients received 8 weeks of treatment, and 3 patients received 12 or more weeks of treatment. For patients that received at least 4 weeks of treatment, the average AFP value stabilized during the first 4 weeks of treatment. Two patients experienced an AFP decrease of >30%, approximately 37 and 40% decreases at the nadir. One patient had stable disease of 9 months. Major side effects were fever, fatigue, rash, and local injection site reaction of swelling, redness, and tenderness. Conclusion: This case series of advanced HCC indicates that mistletoe extract VF-2 may have potential biological activity against HCC for selected patients. Research is needed to identify the active compound and predictive markers of response.

Sign in / Sign up

Export Citation Format

Share Document